Association for Molecular Pathology v. Myriad Genetics: Can You Patent a Human Gene?

LEGAL DISCLAIMER: This article provides general, informational content for educational purposes only. It is not a substitute for professional legal advice from a qualified attorney. Always consult with a lawyer for guidance on your specific legal situation.

Imagine a prospector discovers a new, unique type of tree in the Amazon rainforest whose wood is naturally resistant to fire. Can he get a `patent` on the tree itself, preventing anyone else from studying or using it? The law says no. The tree is a product of nature, something that exists in the world without human invention. However, if that same prospector invents a brand-new process to turn that wood into a transparent, stronger-than-steel building material, he can patent that new material. He didn't invent the tree, but he did invent a new and useful application of it. The landmark supreme_court_of_the_united_states case, Association for Molecular Pathology v. Myriad Genetics, Inc., applied this same logic to the human body. For decades, a company called Myriad Genetics held patents on two specific human genes, brca1_gene and BRCA2, which are strongly linked to breast and ovarian cancer. They argued that because they were the first to “isolate” these genes from the human genome, they owned them. This meant only they could perform tests for these cancer risks, and they charged thousands of dollars. In 2013, the Supreme Court unanimously declared this was wrong. A company cannot patent a human gene as it is found in nature. This decision fundamentally changed medicine, research, and the entire biotechnology industry, making critical health information more accessible and affordable for millions.

• Key Takeaways At-a-Glance:
  • The Ruling: In Association for Molecular Pathology v. Myriad Genetics, the Supreme Court ruled that naturally occurring human genes cannot be patented because they are “products of nature.”
  • The Impact on You: This decision broke a monopoly on brca1_gene genetic testing, dramatically lowering costs, increasing testing options, and allowing patients to get second opinions.
  • The Nuance: The Court did rule that a synthetic, lab-created form of DNA called complementary DNA (cDNA) can be patented, preserving an incentive for innovation in the intellectual_property landscape of biotechnology.

In the early 1990s, the world of medical science was buzzing with the race to map the human genome. One of the most urgent pursuits was to identify specific genes linked to hereditary cancers. Researchers at the University of Utah, in collaboration with other institutions, made a monumental breakthrough: they identified two human genes, dubbed BRCA1 and BRCA2. They discovered that specific mutations in these genes dramatically increased a woman's risk of developing breast and ovarian cancer. This was a life-changing discovery. It meant that women could be tested to see if they carried these mutations, allowing them and their doctors to make proactive, life-saving decisions about monitoring and preventative care. One of the key players in this research was a private company, Myriad Genetics, a spin-off from the University of Utah.

Armed with this groundbreaking discovery, Myriad Genetics, along with the u.s._patent_and_trademark_office (USPTO), did something that would set the stage for a decade-long legal battle. They filed for, and were granted, a series of patents covering the isolated BRCA1 and BRCA2 genes themselves. What did this mean in practice?

• Exclusive Rights: Myriad claimed it had the sole and exclusive right to isolate these genes from a person's body.
• Control Over Testing: It also claimed the exclusive right to perform any diagnostic test on these genes. No other lab, hospital, or research institution in the United States could legally offer BRCA testing.
• High Costs: Without competition, Myriad could set its own price. For years, their BRACAnalysis test cost over $3,000, creating a significant financial barrier for many at-risk patients.
• Stifled Research: Myriad's patents created a “chilling effect” on medical research. Scientists who wanted to study the BRCA genes for new therapies or to improve diagnostic methods lived in fear of being sued for `patent_infringement`. The flow of scientific collaboration and innovation was severely restricted.

The situation became untenable for many in the medical and scientific communities. Patients were unable to get second opinions on their test results. Researchers were blocked from making new discoveries. Genetic counselors were frustrated by the limitations placed on their ability to help families. In 2009, a diverse and powerful coalition decided to fight back. Led by the american_civil_liberties_union (ACLU) and the Public Patent Foundation, the plaintiffs in the case represented a wide swath of society. They included:

• The Association for Molecular Pathology (AMP): The lead plaintiff, representing over 9,000 researchers and laboratorians.
• Individual Researchers: Scientists who were personally blocked from their work by Myriad's patents.
• Genetic Counselors: Professionals who needed access to testing for their patients.
• Patient Advocacy Groups: Organizations like Breast Cancer Action.
• Individual Patients: Women who were either unable to afford the test or who wanted a second opinion on their results.

They filed a lawsuit against Myriad Genetics and the USPTO, arguing a simple but profound point: human genes should not be patentable. Their case methodically moved through the court system, from the District Court to the Federal Circuit Court of Appeals, before ultimately landing before the highest court in the land.

On June 13, 2013, the Supreme Court of the United States issued a unanimous 9-0 decision that sent shockwaves through the worlds of law, medicine, and business. The opinion, written by Justice Clarence Thomas, was remarkably clear and direct. To understand its impact, we must break down the two key questions the Court answered.

The central legal issue revolved around a concept known as the product_of_nature_doctrine. This long-standing principle of patent law states that you cannot patent things that are found in nature, like a new mineral, a plant, or a physical law like gravity. To be patentable, an invention must be something new and useful that was created by human ingenuity. Myriad argued that by “isolating” the BRCA genes—separating them from the rest of the chromosome—they had created something new. The Court had to decide if this act of isolation was enough to turn a product of nature into a patentable human invention. They analyzed two different types of DNA involved in Myriad's patents.

• What It Is: Genomic DNA (gDNA) is the DNA exactly as it is found inside your body's cells. When Myriad “isolated” the BRCA gene, they located the gene on the chromosome and then snipped it out from the surrounding genetic material.
• Myriad's Argument: Myriad claimed that because the isolated gene was no longer attached to the chromosome, it was a new chemical entity distinct from what was in the body.
• The Court's Reasoning: The Supreme Court forcefully rejected this argument. Justice Thomas wrote that Myriad “did not create anything.” The company had simply found an important gene, but the genetic information—the crucial sequence of nucleotides that holds the instructions for life—was the same inside the body as it was in Myriad's lab. The Court held that simply separating a gene from its natural environment is not an act of invention. To use our earlier analogy, this was like finding the fire-resistant tree but not inventing anything new from it.
• The Holding: Naturally occurring, isolated DNA is a product of nature and is not patent-eligible.

• What It Is: Complementary DNA, or cDNA, is different. It is a synthetic molecule created in a laboratory. In human DNA, genes contain coding sections (exons) and non-coding sections (introns). When your body reads a gene to create a protein, it first makes an RNA copy and then edits out the non-coding introns. cDNA is created by scientists who use an enzyme to make a DNA copy of that edited RNA molecule. The result is a DNA sequence that contains only the protein-coding exons.
• Myriad's Argument: Myriad argued that since cDNA does not exist in nature and is created through a laboratory process, it is a human invention.
• The Court's Reasoning: The Supreme Court agreed. They noted that the lab technician “unquestionably creates something new” when making cDNA. Because the non-coding introns are removed, the resulting cDNA molecule has a different nucleotide sequence from the natural gene. It is a new creation, not merely a discovery. This was like the prospector inventing a new, transparent building material from the natural wood.
• The Holding: Synthetic cDNA is not a product of nature and is patent-eligible.

This nuanced decision achieved a critical balance. It freed the human genome for research and competition while still providing an incentive for companies like Myriad to invest in creating new, synthetic diagnostic tools and therapies.

The Supreme Court's ruling in *Myriad* wasn't just an abstract legal debate; it had immediate and profound consequences for patients, doctors, researchers, and the entire healthcare industry. The decision effectively broke Myriad's monopoly overnight.

For the average person, especially those with a family history of cancer, the impact was life-changing.

• Dramatic Cost Reduction: Within days of the ruling, other labs began offering BRCA testing. With competition flooding the market, the price plummeted from over $3,000 to, in many cases, a few hundred dollars. Today, many tests are fully covered by insurance.
• Access to Second Opinions: Patients were no longer locked into a single provider. If they received a confusing or concerning result from one lab, they could have their test run by another to confirm the findings—a standard practice in almost every other area of medicine.
• More Comprehensive Testing: Competitors soon offered more advanced tests, including large-panel tests that could screen for mutations in BRCA1, BRCA2, and dozens of other cancer-related genes simultaneously, often for less than the cost of Myriad's original two-gene test.
• Patient Empowerment: The ruling affirmed the idea that our genes belong to us, not to a corporation. It empowered patients to take control of their genetic information and make healthcare decisions without being constrained by a single company's business model.

The scientific community celebrated the decision as a major victory for open research and medical progress.

• Freedom to Research: The “chilling effect” of Myriad's patents vanished. Scientists could now freely study the BRCA genes to better understand how they function, identify new mutations, and develop novel therapies without the threat of a lawsuit. This accelerated the pace of discovery.
• Innovation in Diagnostics: Labs and universities were free to develop and validate their own, often better and more efficient, testing methods. This led to faster turnaround times and more accurate results for patients.
• Collaborative Science: The decision fostered a more collaborative environment. Instead of hoarding data, researchers could more openly share their findings about gene mutations, contributing to large public databases that benefit everyone.

While some in the biotech industry initially feared the ruling would destroy innovation, it ultimately provided clarity and shifted the focus of intellectual_property strategy.

• Focus on Application, Not Discovery: The decision sent a clear message: you cannot patent a discovery of nature, but you can patent a novel application of that discovery. Companies now focus their patent strategies on new diagnostic methods, unique therapeutic drugs, lab-created genetic sequences (like cDNA), and gene-editing technologies like `crispr`.
• A Clearer Legal Landscape: The unanimous ruling provided a bright-line rule that was easy to understand: natural DNA is off-limits, synthetic DNA is not. This legal certainty allows companies to invest with a clearer understanding of what is and is not protectable.
• Preserving a Path to Profitability: By upholding the patentability of cDNA and other applications, the Court ensured that the financial incentives for research and development, which are critical for funding expensive new drugs and technologies, remained intact.

The *Myriad* decision was not the final word on patenting life sciences discoveries. It served as a foundational precedent that courts and the USPTO have continued to interpret and apply to new technologies. The legal questions have shifted from “Can you patent a gene?” to “Can you patent a method of diagnosing a disease by observing a natural phenomenon?”

Decided just a year before *Myriad*, the *Mayo* case set the stage for the Court's reasoning.

• The Backstory: Prometheus patented a method for determining the proper dosage of a drug by observing a patient's metabolic response. They argued the specific correlation they discovered was an invention.
• The Legal Question: Is a method patentable if it consists of observing a natural law or phenomenon and then suggesting a course of action?
• The Court's Holding: The Supreme Court unanimously said no. The relationship between the drug and the patient's metabolism was a natural phenomenon. The patent's “steps” were merely instructions to observe that phenomenon. This was a critical precedent, establishing that one cannot patent a law of nature. The *Myriad* court relied heavily on *Mayo* to conclude that the genetic sequence was a product of nature, just like the metabolic relationship in this case.

This case tested the limits of *Myriad* and *Mayo* in the context of a revolutionary new diagnostic technique.

• The Backstory: Sequenom discovered that cell-free fetal DNA circulates in a pregnant mother's blood. They patented a non-invasive method to test this fetal DNA for genetic abnormalities. This was a groundbreaking discovery.
• The Legal Question: Is a new and useful diagnostic method that is based on the discovery of a natural phenomenon (fetal DNA in maternal blood) patentable?
• The Court's Holding: The Federal Circuit Court of Appeals, reluctantly applying the *Mayo* and *Myriad* framework, ruled that the method was not patentable. They reasoned that Sequenom had discovered a natural phenomenon and then applied well-understood, conventional laboratory techniques to it. Even though the discovery was brilliant and had enormous practical benefit, the method itself was deemed an unpatentable application of a natural law. This decision remains highly controversial, with many arguing it has gone too far in limiting patents on valuable diagnostic tools.

The *Myriad* decision reshaped the past, but the questions it raised continue to shape the future. As technology advances at a breathtaking pace, new legal and ethical challenges are constantly emerging.

The legal principles from *Myriad* are now being applied to cutting-edge technologies, creating new controversies:

• Gene Editing (CRISPR): CRISPR-Cas9 is a revolutionary technology that allows scientists to edit genes. While the natural CRISPR system found in bacteria would not be patentable under *Myriad*, the specific, human-engineered tools and methods used to apply it in a lab are the subject of fierce patent battles. The law must now distinguish between the natural biological process and the human-made tool used to harness it.
• Diagnostic Method Patents: The *Ariosa* decision has created significant uncertainty around the patentability of diagnostic tests. Innovators argue that without patent protection, there is little incentive to invest the millions of dollars needed to develop new, life-saving diagnostic methods. The debate rages in Congress and the courts over whether the current legal standard is stifling medical innovation.
• AI and Drug Discovery: As artificial intelligence becomes more involved in identifying drug targets and designing new molecules, new patent questions arise. If an AI system, not a human, discovers a new biological correlation, who is the inventor? Can an AI's discovery be patented at all?

Looking ahead, the next decade will likely focus on two key areas:

• Personalized Medicine: The goal of personalized medicine is to tailor treatments to an individual's unique genetic makeup. This requires vast amounts of genetic data and the development of highly specific therapies. The patent system will need to adapt to protect these hyper-personalized inventions without preventing doctors from providing tailored care.
• Genetic Data Ownership: *Myriad* was about owning a gene; the next battle will be about owning genetic information. As millions of people use services like 23andMe and AncestryDNA, questions about who owns and controls that data, and how it can be used for research and commercial purposes, will become central legal and ethical issues.

The legacy of Association for Molecular Pathology v. Myriad Genetics is that it drew a clear line in the sand, affirming that the building blocks of humanity cannot be monopolized. The ongoing challenge for our legal system is to apply that foundational principle to a future of medicine and technology that we are only just beginning to imagine.

• patent: An exclusive right granted for an invention, allowing the patent holder to exclude others from making, using, or selling it.
• intellectual_property: A category of property that includes intangible creations of the human intellect, such as patents, copyrights, and trademarks.
• supreme_court_of_the_united_states: The highest federal court in the United States, with final appellate jurisdiction over all federal and state court cases.
• product_of_nature_doctrine: A legal principle stating that things discovered in their natural form (e.g., minerals, plants, laws of physics) are not patentable.
• brca1_gene: A human gene that, when mutated, is associated with a significantly increased risk of breast and ovarian cancer.
• genome: The complete set of genetic material present in a cell or organism.
• DNA (Deoxyribonucleic acid): The molecule that carries the genetic instructions for the development, functioning, growth, and reproduction of all known organisms.
• Gene: A specific sequence of nucleotides in DNA or RNA that is located usually on a chromosome and that is the functional unit of inheritance.
• cDNA (Complementary DNA): A synthetic, lab-created DNA molecule synthesized from an edited RNA template, containing only protein-coding exons.
• patent_infringement: The act of making, using, selling, or importing a patented invention without the permission of the patent holder.
• american_civil_liberties_union (ACLU): A non-profit organization whose stated mission is to defend and preserve the individual rights and liberties guaranteed by the U.S. Constitution.
• u.s._patent_and_trademark_office (USPTO): The federal agency responsible for granting U.S. patents and registering trademarks.
• crispr: A family of DNA sequences found in bacteria that is used as a gene-editing tool.

• intellectual_property
• patent_law
• product_of_nature_doctrine
• mayo_v._prometheus
• diamond_v._chakrabarty
• biotechnology_law
• healthcare_law